Deals

Focus Pharmaceuticals Ltd. Acquired by AMCo October 1, 2014

Overview

On October 1, 2014, AMCo (Amdipharm Mercury group) announced the acquisition of Focus Pharmaceuticals (Focus), a specialty pharma business in the UK.

AMCo currently sells niche medicines in over 100 countries worldwide.

Focus predominantly sells branded and generic niche medicines in the UK, but some products are also sold throughout Europe.

Significance

This acquisition keeps with AMCo’s strategy of identifying niche medicines and opportunities to expand its sales base throughout its growing international platform.

AMCo’s product base will be expanded to include Focus’ highly complementary portfolio of niche medicines.

Mark Cresswell, Focus CEO commented: ” This combination with AMCo will enable many of the products developed over the last 10 years to be taken internationally faster and more efficiently than Focus could have taken them.”

Crosstree’s Role

Financial and strategic advisor to Focus Pharmaceuticals.

Sub-Sector

Diagnostics and Tools

Type

Merger and Acquisition

Deal Tags

Diagnostic Laboratory
Pharma Commerizational